Preview

Russian Journal of Cardiology

Advanced search

LIPOPROTEIN(A) MEANING AS AN ADDITIONAL MARKER OF CARDIOVASCULAR RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

https://doi.org/10.15829/1560-4071-2016-6-45-49

Abstract

Aim. To analyze the relation of Lp(a) and atherosclerosis development in familial hypercholesterolemia (FHCE).

Material and methods. Totally, 81 patient with definite FHCE studied, mean age 39,1±0,4 y. o. The participants were selected to two groups: first — with increased level of Lp(a) >0,3 g/L (n=34); mean age — 44,5±0,3; second — with normal Lp(a) <0,3 g/L (n=47, 58,1%); mean age — 37,5±0,3 y. o.

Results. Mean level of Lp(a) in various age persons did not differ significantly. In both subgroups in about a half of all participants there was arterial hypertension (AH) revealed (50,8% and 42,6%, respectively), obesity was diagnosed in one third of both groups, number of smokers was higher in higher Lp(а) group (11,8% and 8,5%). IHD had 25,9% of participants. Revalence of IHD in IHD group was 44, 4%, in non-smoker group — 25,8% (RR 1,72 (0,75; 3,99)), acute myocardial infarction prevalence (MI) in smoking subgroup was — 44,6% versus 13,5% (RR 3,26 (1,26; 8,43)). Among lipid profile parameters LDL level was definitive for IHD development (p=0,012). Presence of obesity increased MI risk 2,54 times in FHCE (OR 2,4 (1,05; 5,63)). With increase of Lp(a) IHD was diagnosed more commonly: 32,4% versus 19%, non-significant (p=0,47). Prevalence of MI in the first group was higher than in the second: 8 (23,5%) and 4 (8,5%), respectively, (OR 3,3 (1,1; 9,8), р=0,03).

Conclusion. In FHCE, the risk of IHD was influenced by traditional RF (smoking, obesity, LDL level).

About the Authors

V. A. Korneva
Петрозаводский государственный университет, Петрозаводск
Russian Federation
Petrozavodsk State University, Petrozavodsk


T. Yu. Kuznetsova
Petrozavodsk State University, Petrozavodsk
Russian Federation


G. P. Tikhova
Institute of Forest of Karelsky Scientific Center of RAS, Petrozavods
Russian Federation


References

1. Kassner U., Schlabs T, Rosada A, Steinhagen-Thiessen E. Lipoprotein(a)-An

2. independent causal risk factor for cardiovascular disease and current therapeutic

3. options. Atheroscler Suppl. 2015 May;18:263-7.

4. Afanas'eva OI, Ezhov MV, Afanas'eva MI, Safarova MS. et al. Connection

5. low-molecular fenotype of apoprotein (a) and concentration of lipoproteid (a) with multifocal atherosclerosis in patients with ischemic heart disease /

6. Ration pharmacotherapy in cardiology 2010-№6(4)-с.474-480. Russian (Афанасьева О.И., Ежов М.В., Афанасьева М.И., Сафарова М.С. и др. Связь низкомолекулярного фенотипа апобелка(а) и концентрации липопротеида(а) с мультифокальным атеросклерозом у больных ишемической болезнью сердца.Рациональная фармакотерапия в кардиологии 2010,6(4):474-480.

7. Safarova MS, Ezhov MV. Evolution of opinion on lipoproteid(a):from biomarker to therapeutic target. Kardilogiia 2015; 55-4.Russian. (Сафарова М.С., Ежов М.В. Эволюция взглядов на липопротеид(а): от биомаркера до терапевтической мишени. Кардиология 2015; 55-4).

8. Jurgens G, Chen Q, Esterbauer H. et al. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). Arterioscler Thromb 1993;13(11):1689–1699.

9. Kosсhinsky M, Marcovina S. Lipoprotein(a). in Ballantyne C.M. et al, editor. Clinical Lipidology: a companion to Braunwald’s heart disease. Saunders, and imprint of Elsevier Inc; 2009. р.130-143.

10. Bennet A, Di Angelantonio E, Erqou S. et al. Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease Large-Scale Prospective Data. Arch Intern Med 2008;168(6):598-608.

11. Kamstrup PR., Tybjaerg –Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA.2009;301:2331-9.

12. Nordestgaard BG, Chapman MJ, Ray K. et al. European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as cardiovascular risk factor: current status. Eur. Heart J.2010; 31: 2844-53.

13. Wiegman A, Gidding SS, Watts GF.et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015; May 25: 1-17.

14. Bos S, Duvekot MH, Touw-Blommesteijn AC. et al. Lipoprotein (a) levels are not associated

15. with carotid plaques and carotid intima media thickness in statin-treated

16. patients with familial hypercholesterolemia. Atherosclerosis. 2015 Jul

17. ; 242(1): 226-229.

18. Erqou S, Kaptoge S, Perry PL et al. Emerging Risk Factors Collaboration Lipoprotein (a) concentration and the risk of coronary heart disease , stroke and nonvascular mortality. JAMA 2009; 302: 412-423.

19. Holmes DT, Schick BA, Humphiries KH, Froblich J. Lipoprotein (a) as independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51:2067-2073.

20. Yeang C, Tsimikas S. HDL-C, ABCA1-mediated cholesterol efflux, and

21. lipoprotein(a): insights into a potential novel physiologic role of

22. lipoprotein(a).J Lipid Res. 2015 Jul; 56(7) : 1241-4.


Supplementary files

1. список сокращений
Subject
Type Исследовательские инструменты
Download (13KB)    
Indexing metadata ▾
2. Таблица1
Subject
Type Исследовательские инструменты
Download (13KB)    
Indexing metadata ▾
3. Таблица2
Subject
Type Исследовательские инструменты
Download (14KB)    
Indexing metadata ▾
4. Таблица3
Subject
Type Исследовательские инструменты
Download (14KB)    
Indexing metadata ▾
5. Таблица4
Subject
Type Исследовательские инструменты
Download (15KB)    
Indexing metadata ▾
6. таблица5
Subject
Type Исследовательские инструменты
Download (14KB)    
Indexing metadata ▾
7. таблица 6
Subject
Type Исследовательские инструменты
Download (14KB)    
Indexing metadata ▾
8. Таблица 7
Subject
Type Исследовательские инструменты
Download (13KB)    
Indexing metadata ▾

Review

For citations:


Korneva V.A., Kuznetsova T.Yu., Tikhova G.P. LIPOPROTEIN(A) MEANING AS AN ADDITIONAL MARKER OF CARDIOVASCULAR RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA. Russian Journal of Cardiology. 2016;(6):45-49. (In Russ.) https://doi.org/10.15829/1560-4071-2016-6-45-49

Views: 711


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)